ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
21.54
-0.01 (-0.05%)
Jul 21, 2025, 4:00 PM - Market open
ArriVent BioPharma Employees
ArriVent BioPharma had 52 employees as of December 31, 2024. The number of employees increased by 12 or 30.00% compared to the previous year.
Employees
52
Change (1Y)
12
Growth (1Y)
30.00%
Revenue / Employee
n/a
Profits / Employee
-$2,451,115
Market Cap
786.72M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | 12 | 30.00% |
| Dec 31, 2023 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
AVBP News
- 1 day ago - ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - GlobeNewsWire
- 20 days ago - Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 20 days ago - ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 20 days ago - ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study - GlobeNewsWire
- 4 weeks ago - ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC - GlobeNewsWire
- 2 months ago - ArriVent BioPharma Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - GlobeNewsWire